Ji Yu

One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab

R. Wells, A. Bosi, A. Gaya, 2020, European journal of haematology.

Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies

J. Lee, S. Langemeijer, K. Usuki, 2022, European journal of haematology.

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

R. Wells, A. Bosi, A. Gaya, 2019, Blood.